Aurinia Pharmaceuticals Inc (AUPH)vsRoyalty Pharma Plc (RPRX)
AUPH
Aurinia Pharmaceuticals Inc
$17.23
-3.24%
HEALTHCARE · Cap: $2.26B
RPRX
Royalty Pharma Plc
$56.23
+2.82%
HEALTHCARE · Cap: $31.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 718% more annual revenue ($2.44B vs $298.30M). AUPH leads profitability with a 100.0% profit margin vs 33.9%. AUPH trades at a lower P/E of 8.1x. AUPH earns a higher WallStSmart Score of 69/100 (B-).
AUPH
Strong Buy69
out of 100
Grade: B-
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AUPH.
Margin of Safety
-57.2%
Fair Value
$34.53
Current Price
$56.23
$21.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 53 in profit
Keeps 100 of every $100 in revenue as profit
Strong operational efficiency at 53.3%
Earnings expanding 56.3% YoY
Conservative balance sheet, low leverage
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
No major concerns identified
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AUPH
The strongest argument for AUPH centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 100.0% and operating margin at 53.3%. Revenue growth of 24.4% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : AUPH
No major red flags identified for AUPH, but monitor valuation.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
AUPH profiles as a growth stock while RPRX is a mature play — different risk/reward profiles.
AUPH carries more volatility with a beta of 1.43 — expect wider price swings.
AUPH is growing revenue faster at 24.4% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
AUPH scores higher overall (69/100 vs 65/100), backed by strong 100.0% margins and 24.4% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aurinia Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Visit Website →Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?